**AUB KQ1 Evidence Table (Reference ID #871)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author**:  Bonnar and Sheppard,  1996  **Country**:  Ireland  **Enrollment** **period**:  NR  **Intervention** **setting**:  University department of OB-GYN  **Funding**:  Health Research Board of Ireland and Pharmacia, Sweden  **Author industry relationship disclosures:**  None  **Study Design:**  RCT  **Blinding**:  None | **Intervention/ Comparator:**  Tranexamic acid 1 g six hourly; mefenamic acid 500 mg eight hourly; ethamsylate 500 mg six hourly  All treatments taken for five days from day 1 of bleeding for three cycles  **Groups:**  **G1:** Tranexamic acid  **G2:** Mefenamic acid  **G3:** Ethamsylate  **Followup:**  3 cycles | **Inclusion criteria:**   * Aged 35 to 46 years * Complaint of regular heavy menstrual bleeding   Mean menstrual loss >80 ml measured over three consecutive menstrual periods before treatment  **Exclusion criteria:**  Organic causes of menorrhagia excluded by hysteroscopy, endometrial biopsy, cervical smear test 3 to 12 months before enrollment  History of renal or hepatic impairment  Previous thromboembolic disease  Inflammatory bowel disease  Peptic or intestinal ulceration  Coagulation or fibrinolytic disorders  **N at enrollment:**  **G1:** 27  **G2:** 25  **G3:** 29  **N at followup:**  **G1:** 26  **G2:** 23  **G3:** 27  **Age, mean years ± SD:**  **G1:** 40 ± 5  **G2:** 38 ± 8  **G3:** 37 ± 8  **BMI:**  NR  **Height, mean cm ± SD:**  **G1:** 160 ± 6  **G2:** 161 ± 6  **G3:** 164 ± 7  **Weight, mean kg ± SD:**  **G1:** 66 ± 10  **G2:** 66 ± 12  **G3:** 64 ± 9  **Parity:**  NR  **Race/ethnicity:**  NR | **Bleeding:**  MBL measured by alkaline hematin method during 3 cycles pretreatment, mean ml:  **G1:** 164  **G2:** 186  **G3:** 170  MBL duration, mean days ± SD:  **G1:** 5.5 ± 1.4  **G2:** 5.8 ± 1.3  **G3:** 5.7 ± 1.1  Sanitary towels, mean ± SD:  **G1:** 23 ± 7.0  **G2:** 25 ± 7.0  **G3:** 25 ± 9.0 | **Bleeding:**  MBL measured by alkaline hematin method during 3 treatment cycles, mean ml:  **G1:** 75  **G2:** 148  **G3:** 175  MBL change, n (%):  Less:  **G1:** 18 (69)  **G2:** 13 (57)  **G3:** 12 (44)  Same:  **G1:** 4 (15)  **G2:** 5 (22)  **G3:** 5 (19)  Greater:  **G1:** 4 (15)  **G2:** 4 (17)  **G3:** 8 (30)  Dysmenorrhea change, n (%):  Better:  **G1:** 5 (19)  **G2:** 3 (13)  **G3:** 1 (4)  Same:  **G1:** 14 (54)  **G2:** 11 (48)  **G3:** 19 (70)  Worse:  **G1:** 7 (27)  **G2:** 8 (35)  **G3:** 4 (15)  MBL duration, mean days ± SD:  **G1:** 4.9 ± 1.8  **G2:** 5.3 ± 1.3  **G3:** 5.7 ± 2.0  Sanitary towels, mean ± SD, p value:  **G1:** 20 ± 6.0, p<0.01  **G2:** 23 ± 9.0, p<0.05  **G3:** 25 ± 9.0  **G1 vs. BL:** p<0.01  **G2 vs. BL:** p<0.05  **G3 vs. BL:** p=NS  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  Wish to continue treatment at end of study, n (%):  **G1:** 20 (77)  **G2:** 17 (74)  **G3:** NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  NR  **Adverse events:**  Withdrawal,a n:  **G1:** 4  **G2:** 3  **G3:** 11  Withdrawal due to unwanted event such as nausea, headache or dizziness, n:  **G1:** 3  **G2:** 1  **G3:** 4 | **Overall quality:**  Poor  **Risk of bias:**  Randomization:  Low  Allocation concealment:  Unclear  Selective reporting:  Unclear  Blinding patients/personnel:  High  Blinding outcome assessment:  High  Incomplete outcome reporting:  Low  Other:  Low |

**Table Notes**: a Reasons for withdrawal: poor efficacy (G3: n=5; G2: n=1); unwanted event such as nausea, headache and dizziness (G1: n=3; G2: n=1; G3: n=4).